Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The RESET System Pivotal Clinical Trial (Protocol Revision K) (STEP-1)

7 octobre 2026 mis à jour par: Morphic Medical Inc.

Une étude randomisée, multicentrique et pivot d'efficacité et d'innocuité évaluant le système EndoBarrier® pour l'amélioration de la glycémie chez les patients atteints de diabète de type 2 et d'obésité insuffisamment contrôlés

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.

A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Aperçu de l'étude

Statut

Recrutement

Les conditions

Description détaillée

The objective of this study is to evaluate the safety and effectiveness of the RESET System when used with moderate intensity lifestyle and dietary counseling and medical management, in patients with baseline HbA1c ≥ 7.5% and ≤10%, and BMI ≥ 30 kg/m2 and ≤ 50kg/m2, whose diabetes medications consist of at least dual therapy for 3 months, yet have not achieved adequate HbA1c control (<7.5%).

Specific objectives of this study are:

  1. To determine if the RESET System significantly improves glycemic control
  2. To determine that the RESET System can be safely used to improve glycemic control

Type d'étude

Interventionnel

Inscription (Estimé)

264

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Arizona
      • Gilbert, Arizona, États-Unis, 85234
        • Recrutement
        • Banner Health
        • Chercheur principal:
          • Neil Sharma, MD
        • Contact:
      • Tucson, Arizona, États-Unis, 85710
        • Recrutement
        • M3 Wake Research
        • Contact:
        • Chercheur principal:
          • David Alster, MD
    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20010
        • Recrutement
        • MedStar Health Research Institute
        • Chercheur principal:
          • John Brebbia, MD
        • Contact:
    • Florida
      • Boynton Beach, Florida, États-Unis, 33435
      • Miami, Florida, États-Unis, 33140
        • Recrutement
        • HCA Health Research Institute
        • Contact:
        • Chercheur principal:
          • Nestor De La Cruz, MD
      • Miami, Florida, États-Unis, 33143
        • Recrutement
        • UMiami
        • Contact:
        • Chercheur principal:
          • Robert Cubas
      • Miami Beach, Florida, États-Unis, 33140
        • Recrutement
        • Quantum Clinical Trials
        • Chercheur principal:
          • George Azar, MD
        • Contact:
      • Orange City, Florida, États-Unis, 32763
      • Orlando, Florida, États-Unis, 32806
        • Recrutement
        • Orlando Health
        • Contact:
        • Chercheur principal:
          • Andre Texeira, MD
      • Plant City, Florida, États-Unis, 33563
        • Recrutement
        • Denali Health Plant City
        • Contact:
        • Chercheur principal:
          • Luis Aponte, MD
      • Pompano Beach, Florida, États-Unis, 33060
        • Recrutement
        • Clinical Research Center of Florida
        • Chercheur principal:
          • Howard Koch, MD
        • Contact:
      • West Palm Beach, Florida, États-Unis, 33407
        • Pas encore de recrutement
        • Health Synergy Clinical Research
        • Chercheur principal:
          • Robert Dudley, MD
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30083
        • Recrutement
        • Denali Health Atlanta
        • Contact:
          • Maria Johnson
        • Contact:
      • Marietta, Georgia, États-Unis, 30060
        • Recrutement
        • Drug Studies America
        • Contact:
        • Chercheur principal:
          • Glenn Gatipon, MD
      • Snellville, Georgia, États-Unis, 30078
    • Louisiana
      • Lake Charles, Louisiana, États-Unis, 70605
        • Recrutement
        • Elevate Clinical Research, Lake Charles
        • Contact:
        • Chercheur principal:
          • Francisco Marrero, MD
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Recrutement
        • Brigham and Women's Hospital
        • Chercheur principal:
          • Christopher C Thompson, MD
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Recrutement
        • Michigan Medicine, Division of Gastroenterology and Hepatology
        • Chercheur principal:
          • Allison R Schulman, MD
        • Contact:
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic
        • Contact:
        • Chercheur principal:
          • Dan Maselli, MD
    • New York
      • New York, New York, États-Unis, 10021
        • Recrutement
        • Weill Cornell Medicine
        • Chercheur principal:
          • Reem Sharaiha, MD
        • Contact:
    • Texas
      • Atascocita, Texas, États-Unis, 77346
        • Recrutement
        • Elevate Clinical Research, Atascocita
        • Contact:
        • Chercheur principal:
          • Maria Berdayes, MD
      • Dallas, Texas, États-Unis, 75224
        • Recrutement
        • M3 Wake Research
        • Contact:
        • Chercheur principal:
          • Carlos Arauz-Pacheco, MD
      • DeSoto, Texas, États-Unis, 75115
        • Recrutement
        • Epic Medical Research
        • Chercheur principal:
          • Haresh Boghara, MD
        • Contact:
      • Forney, Texas, États-Unis, 75126
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • Baylor College of Medicine
        • Chercheur principal:
          • Wasif M Abidi, MD
        • Contact:
      • Houston, Texas, États-Unis, 78504
        • Recrutement
        • Elevate Clinical Research, Houston
        • Chercheur principal:
          • Joe Pouzar, MD
        • Contact:
      • Prosper, Texas, États-Unis, 75078

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

22 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥22 years and ≤ 65 years
  2. Have understood and signed the approved informed consent form
  3. Diagnosis of type 2 diabetes
  4. HbA1c ≥ 7.5% and ≤10%
  5. BMI ≥30kg/m2 and ≤ 50kg/m2
  6. Willing and able to comply with study requirements
  7. Documented negative pregnancy test in women of childbearing potential
  8. Women of childbearing potential not intending to become pregnant (continue to be on an approved form of birth control) for the duration of their trial participation, including post explant period. Women of child-bearing age without known sterilization will be placed on 1 form of birth-control to prevent unwanted pregnancies
  9. At least one year of medical records available, including detailed medical therapy and dosing information
  10. Failed to achieve adequate HbA1c reduction (<7.5%) after dual therapy for at least 3-month stable dosage of diabetes medication(s), including insulin, metformin, SGLT-2 inhibitor, GLP-1 RA, Dual GLP-1/GIPR agonist or, other medications including meglitinides, sulfonylureas, thiazolidinediones, or DPP-4s.

Exclusion Criteria:

  1. Previous treatment with the RESET System
  2. Previous GI surgery that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner, or abnormal GI anatomical finding that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner
  3. Hypoglycemia and/or DKA/HHNK in the last 6 months requiring 3rd party assistance.
  4. Known history of liver disease (e.g., viral or autoimmune etiology, METAVIR grade 2 or higher fibrosis/cirrhosis from a biopsy within the past 6 months, but not including incidental fatty liver)
  5. eGFR of less than 45 ml/min/1.73 m2
  6. Prior history of an abscess requiring hospitalization, intravenous antibiotics or drainage
  7. Previous treatment for severe liver disease and/or biliary tract disease, including but not limited to, surgery, bile duct dilatation, and stent placement
  8. Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis
  9. Fasting C-peptide < 1.0 ng/mL
  10. Triglyceride level > 600 mg/dL
  11. Vitamin D deficiency (<20ng/ml)
  12. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter, or known coagulopathy
  13. Height < 5 feet (152.4 cm)
  14. Current alcohol addiction, current drug addiction or usage, of drugs such as, narcotics, opiates, or benzodiazepines and other addictive tranquilizers
  15. History of pancreatitis, including gallstone related pancreatitis (subsequent to which patient has cholecystectomy)
  16. Diagnosis of osteopenia or osteoporosis or currently taking denosumab, romosozumab-aqqg, bisphosphonates or teriparatide
  17. Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)
  18. Active or recent (less than 12 months) gastroesophageal reflux disease (GERD), unless treated with H2Ras not PPI.
  19. Uncontrolled thyroid disease, including a history of thyroid cancer, hyperthyroidism, or taking thyroid hormone for any reason other than primary hypothyroidism (TSH level must be between 0.4-4)
  20. Currently taking prescription antithrombotic therapy (e.g. anticoagulant or antiplatelet agent) within 10 days prior to randomization and/or there is a need or expected need to use during the trial 9 months post implant procedure
  21. Currently taking the following medications (within 30 days prior to randomization) and/or there is a need or expected need to use these medications during the trial 12 months post index procedure: Restricted Medications/Supplements Systemic corticosteroids Proton Pump Inhibitor (PPI) Drugs known to affect GI motility (e.g.metoclopramide) Prescription or over-the-counter weight loss medication(s) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), aspirin, ibuprofen, and other anti-inflammatory medication for study duration Medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) Supplements that are known or suspected to increase bleeding risk including but not limited to: Gingko biloba Ginseng Vitamins C & E Turmeric St. John's wort Evening primrose oil Feverfew Green Tea Extract
  22. Active H. pylori
  23. History of Crohn's disease, atresias or untreated stenoses
  24. Abnormal pathologies or conditions of the gastrointestinal tract, including ulcers or upper gastrointestinal bleeding conditions within 3 months of randomization
  25. Patients may be disqualified for study inclusion for any condition determined by the PI that places patient at undue risk.
  26. Poor dentition not allowing complete chewing of food
  27. Enrolled in another investigational study within 3 months of screening for this study (enrollment in observational studies is permitted)
  28. Residing in a location without ready access to study site medical resources
  29. Documented weight loss of 5% total body weight (TBW) anytime during the 3 months preceding randomization
  30. Positive Fecal Immunochemical Test (FIT)
  31. History or observation of psychological disorder or behavior which could preclude compliance to the treatment and follow up plan
  32. No access to an active telephone and internet service for provision of Follow Up Schedule calls and electronic diary
  33. Having donated blood or received a blood transfusion in the 90 days prior to baseline labs. Patients should agree not to donate blood during the study
  34. Any condition that increases red cell turnover, such as thalassemia
  35. Existence of (>5 cm string test) Pseudomonas aeruginosa, Stenotrophomonas maltophilia and/or Klebsiella pneumoniae serotype K1 and K36. A known sensitivity to nickel or titanium

37. Do not meet the screening criteria for Fibroscan (i.e., Fibroscan unsafe, or Fibroscan conditional but not appropriate for the region of interest 38. History of myocardial infarction, stroke, or hospitalization for heart failure 39. History Afib and/or cardiac arrythmias 40. History of unstable angina 41.History of new or worsening signs or symptoms of CAD within the last 3 months 42.Any contraindication to general anesthesia or high risk for general anesthesia as determined by anesthesiologist (e.g., ASA score 4 or higher)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: RESET Treatment Arm

Patients in ARM 1, will receive an upper endoscopy and will be treated with the RESET Liner

The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.

Autres noms:
  • Doublure de dérivation duodénale-jéjunale (DJBL)
  • EndoBarrière
  • Manchon de RÉINITIALISATION
Comparateur factice: Sham Control Arm

Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the RESET Liner.

Patient receives upper endoscopy but no treatment

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in HbA1c
Délai: 9 Months

Change in HbA1c value from baseline to 9 months.

9 Months
SAE Rate
Délai: 9 months

Incidence of serious adverse events

9 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
HbA1c Reduction
Délai: 9 and 21 months

Proportion of patients who achieve an HbA1c reduction ≥0.5%

9 and 21 months
Weight Loss
Délai: 9 and 21 months

Proportion of patients who achieve percent total body weight loss ≥ 5% from baseline

9 and 21 months
Insulin use
Délai: 9 and 21 months

Reduction in percentage insulin units per day

9 and 21 months
Fasting blood glucose level
Délai: 9 and 21 months

Reduction in fasting blood glucose values

9 and 21 months
Diabetes Treatment Satisfaction Questionnaire
Délai: 9 and 21 months

Change from baseline in treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire (DTSQ) (0-6, 0=Very dissatified, 6=Very satisfied)

9 and 21 months
Impact of Weight on Quality of Life
Délai: 9 and 21 months

Impact of weight on quality of life (IWQOL) questionnaire change from baseline (0-100, 0=Worst, 100=Best quality of life)

9 and 21 months
EQ-5D
Délai: 9 and 21 months

Change from baseline in treatment satisfaction using EuroQol-5D (1-5, 1=No problem, 5=Extreme problems)

9 and 21 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
% HbA1c reduction
Délai: 9 and 21 months

Proportion of patients who achieve an HbA1c reduction of ≥0.5%, ≥1%, ≥1.5% and ≥2%

9 and 21 months
Total Body Weight
Délai: 9 and 21 months

Proportion of patients who achieve a % total body weight loss of ≥5%, ≥10%, and ≥15%

9 and 21 months
Insulin Units
Délai: 9 and 21 months

Proportion of patients who achieve a reduction in total number of insulin units per day of ≥25%, ≥50%, ≥75% and ≥100%

9 and 21 months
HbA1c Value
Délai: 9 and 21 months

Proportion of patients who achieve an HbA1c of <7%

9 and 21 months
Insulin Dosage
Délai: 9 and 21 months

Proportion of patients reducing insulin dosage

9 and 21 months
Non-insulin Medication use
Délai: 9 and 21 months

Proportion of patients reducing dosage of non-insulin diabetes medications

9 and 21 months
Cholesterol
Délai: 9 and 21 months

Reduction in LDL cholesterol

9 and 21 months
Triglycerides
Délai: 9 and 21 months

Reduction in triglycerides

9 and 21 months
Blood Pressure
Délai: 9 and 21 months

Reduction in systolic blood pressure values

9 and 21 months
Vitamin D Levels
Délai: 9 and 21 months

Changes in vitamin D levels

9 and 21 months
Vitamin D Supplementation
Délai: 9 and 21 months

Average vitamin D supplementation levels required to maintain normal vitamin D levels

9 and 21 months
Vitamin D Refraction
Délai: 9 and 21 months

Proportion of patients refractory to vitamin D supplementation

9 and 21 months
Serum Creatinine
Délai: 9 and 21 months

Change in serum creatinine levels

9 and 21 months
eGFR
Délai: 9 and 21 months

Change in eGFR levels

9 and 21 months
Serum Creatinine Levels
Délai: 9 and 21 months

Proportion of patients with doubling of serum creatinine levels

9 and 21 months
MAFLD - Fatty Liver
Délai: 9 and 21 months

Absolute and magnitude reductions in hepatic fat fraction

9 and 21 months
MASH - Liver Stiffness
Délai: 9 and 21 months

Reduction in liver stiffness

9 and 21 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Christopher C Thompson, MD, Brigham and Women's Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 septembre 2019

Achèvement primaire (Estimé)

30 décembre 2027

Achèvement de l'étude (Estimé)

30 septembre 2029

Dates d'inscription aux études

Première soumission

20 septembre 2019

Première soumission répondant aux critères de contrôle qualité

23 septembre 2019

Première publication (Réel)

24 septembre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner